Cardiology

The CGTLive™ Cardiology specialty topic page contains video interviews with key opinion leaders in the field of cardiology and up-to-date clinical news coverage on the latest cardiology gene and cell therapies for heart disease. It houses information on relevant FDA actions, clinical guideline updates, and clinical trial findings related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for heart conditions.

Latest News

Around the Helix: Cell and Gene Therapy Company Updates – January 15, 2025
Around the Helix: Cell and Gene Therapy Company Updates – January 15, 2025

January 15th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Tenaya’s Hypertrophic Cardiomyopathy Gene Therapy TN-201 Well-Tolerated in Early Clinical Data
Tenaya’s Hypertrophic Cardiomyopathy Gene Therapy TN-201 Well-Tolerated in Early Clinical Data

January 9th 2025

Around the Helix: Cell and Gene Therapy Company Updates – January 8, 2025
Around the Helix: Cell and Gene Therapy Company Updates – January 8, 2025

January 8th 2025

CGTLive's 2024 Pillars of Progress: Top News in Cardiology
CGTLive's 2024 Pillars of Progress: Top News in Cardiology

December 30th 2024

Around the Helix: Cell and Gene Therapy Company Updates – December 18, 2024
Around the Helix: Cell and Gene Therapy Company Updates – December 18, 2024

December 18th 2024

More News

Deepak L. Bhatt, MD, MPH, MBA

Deepak L. Bhatt, MD, MPH, MBA, on Adopting Novel Therapies into Cardiovascular Medicine

Deepak L. Bhatt, MD, MPH, MBA
April 30th 2024

The director of the Mount Sinai Fuster Heart Hospital discussed trends in research and challenges with adopting new therapies.

Jonathan W. Weinsaft, MD, Future Research With Gene Therapy for Cardiovascular Disease

Jonathan W. Weinsaft, MD, Future Research With Gene Therapy for Cardiovascular Disease

Jonathan W. Weinsaft, MD
April 27th 2024

The chief of cardiology at Weill Cornell Medical College shared his outlook on the future of gene therapy research in the field.

Around the Helix: Cell and Gene Therapy Company Updates – April 24, 2024

Around the Helix: Cell and Gene Therapy Company Updates – April 24, 2024

Noah Stansfield
April 24th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind – April 19, 2024

CGTLive®’s Weekly Rewind – April 19, 2024

CGTLive Staff
April 19th 2024

Review top news and interview highlights from the week ending April 19, 2024.

Around the Helix: Cell and Gene Therapy Company Updates – April 17, 2024

Around the Helix: Cell and Gene Therapy Company Updates – April 17, 2024

Noah Stansfield
April 17th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind - April 12, 2024

CGTLive®’s Weekly Rewind – April 12, 2024

CGTLive Staff
April 12th 2024

Review top news and interview highlights from the week ending April 12, 2024.

Around the Helix: Cell and Gene Therapy Company Updates – April 10, 2024

Around the Helix: Cell and Gene Therapy Company Updates – April 10, 2024

Noah Stansfield
April 10th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive Weekly Rewind - April 5, 2024

CGTLive®’s Weekly Rewind – April 5, 2024

CGTLive Staff
April 5th 2024

Review top news and interview highlights from the week ending April 5, 2024.

Around the Helix: Cell and Gene Therapy Company Updates – April 3, 2024

Around the Helix: Cell and Gene Therapy Company Updates – April 3, 2024

Noah Stansfield
April 3rd 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Verve Moves on to Second Gen Cardiovascular CRISPR Therapy After Adverse Events

Verve Moves on to Second Gen Cardiovascular CRISPR Therapy After Adverse Events

Victoria Johnson
April 2nd 2024

The sixth participant dosed experienced grade 3 treatment-induced ALT increases and thrombocytopenia.

Around the Helix: Cell and Gene Therapy Company Updates – March 27, 2024

Around the Helix: Cell and Gene Therapy Company Updates – March 27, 2024

Noah Stansfield
March 27th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deepak L. Bhatt, MD, MPH, MBA

Deepak L. Bhatt, MD, MPH, MBA, on Encouraging Data With Gene Editing for Hypercholesteremia

Deepak L. Bhatt, MD, MPH, MBA
March 25th 2024

The director of the Mount Sinai Fuster Heart Hospital shared his optimism on data seen so far with VERVE-101.

Jonathan W. Weinsaft, MD

Jonathan W. Weinsaft, MD, on Working to Bring Novel Therapies to Cardiovascular Disease

Jonathan W. Weinsaft, MD
March 21st 2024

The chief of cardiology at Weill Cornell Medical College discussed gene therapy research into Friedreich ataxia and more.

Around the Helix: Cell and Gene Therapy Company Updates – March 20, 2024

Around the Helix: Cell and Gene Therapy Company Updates – March 20, 2024

Noah Stansfield
March 20th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – March 13, 2024

Around the Helix: Cell and Gene Therapy Company Updates – March 13, 2024

Noah Stansfield
March 13th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Gene Editing Investigations Mature With heart-1 Trial for Familial Hypercholesterolemia

Gene Editing Investigations Mature With heart-1 Trial for Familial Hypercholesterolemia

Victoria Johnson
March 13th 2024

Verve Therapeutics plans to expand evaluations into the US after an IND clearance was delayed by a clinical hold.

Around the Helix: Cell and Gene Therapy Company Updates – March 6, 2024

Around the Helix: Cell and Gene Therapy Company Updates – March 6, 2024

Noah Stansfield
March 6th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 28, 2024

Around the Helix: Cell and Gene Therapy Company Updates – February 28, 2024

Noah Stansfield
February 28th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 21, 2024

Around the Helix: Cell and Gene Therapy Company Updates – February 21, 2024

Noah Stansfield;Victoria Johnson
February 21st 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Roger Hajjar, MD, cofounder of Medera and Sardocor and the director of the Mass General Brigham Gene and Cell Therapy Institute

Sardocor’s Heart Failure Gene Therapy SRD-001 Garners Fast Track Designation as First Patients Are Dosed

Noah Stansfield
February 15th 2024

The first 3 participants in the MUSIC-HFpEF trial have now been dosed with the AAV vector-based gene therapy.

Around the Helix: Cell and Gene Therapy Company Updates – February 14, 2024

Around the Helix: Cell and Gene Therapy Company Updates – February 14, 2024

Noah Stansfield
February 14th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 7, 2024

Around the Helix: Cell and Gene Therapy Company Updates – February 7, 2024

Noah Stansfield
February 7th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – January 31, 2024

Around the Helix: Cell and Gene Therapy Company Updates – January 31, 2024

Noah Stansfield
January 31st 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – January 24, 2024

Around the Helix: Cell and Gene Therapy Company Updates – January 24, 2024

Noah Stansfield
January 24th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – January 17, 2024

Around the Helix: Cell and Gene Therapy Company Updates – January 17, 2024

Noah Stansfield
January 17th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

MultiStem Cell Therapy Not Superior to Placebo in Patients With Ischemic Stroke

MultiStem Cell Therapy Not Superior to Placebo in Patients With Ischemic Stroke

Victoria Johnson
January 16th 2024

Further research is needed to determine if cell therapy may be beneficial to certain subgroups of patients.

Around the Helix: Cell and Gene Therapy Company Updates – January 10, 2024

Around the Helix: Cell and Gene Therapy Company Updates – January 10, 2024

Noah Stansfield
January 10th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

After Exa-Cel: Exploring the Next Wave of CRISPR Gene Editing Strategies

After Exa-Cel: Exploring the Next Wave of CRISPR Gene Editing Strategies

Victoria Johnson
January 3rd 2024

The approval of exa-cel, the first gene editing therapy, may herald a new era in developing gene editing strategies.

Around the Helix: Cell and Gene Therapy Company Updates – January 3, 2024

Around the Helix: Cell and Gene Therapy Company Updates – January 3, 2024

Noah Stansfield
January 3rd 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive's Clinical Trials to Watch in 2024

CGTLive's Clinical Trials to Watch in 2024

Matt Hoffman
January 1st 2024

These, among many others, are some of the key clinical trials of gene, cell, and regenerative therapies that the CGTLive staff will be following throughout 2024.

<123456>
© 2025 MJH Life Sciences

All rights reserved.